The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region
Background: By 2021, the FDA approved the use of the drugs pembrolizumab and atezolizumab in the first-line treatment of patients with high positivity of programmed death ligand-1 (PD-L1) in locally advanced and metastatic non-small-cell-lung cancer (NSCLC). This approval was the result of statistic...
Na minha lista:
Main Authors: | , , , , , , , , |
---|---|
Formato: | Livro |
Publicado em: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Assuntos: | |
Acesso em linha: | Connect to this object online. |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Área/Cota: |
A1234.567 |
---|---|
Cód. Barras: 1 | Disponível |